JUPITER NEUROSCIENCES, INC.

Listed Company

JUNSCIK 0001679628NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-8.64M

Total Assets

$5.56M

Equity

$-1.83M

Shares Out

36.28M

Op. Cash Flow

$-5.41M

Business

JUPITER NEUROSCIENCES, INC. is a clinical-stage research and development company focused on developing an enhanced oral resveratrol platform, JOTROL, to treat neuroinflammation and related neurological and rare diseases. It offers JOTROL as its primary product for therapeutic indications and is developing consumer nutritional products via a planned subsidiary and partnerships. The company’s business segments include clinical development programs (notably JNS115 for Parkinson’s Disease, JNS108 for MCI/early Alzheimer’s, and rare-disease programs JNS101/JNS102/JNS107), licensing and manufacturing partnerships, and business development. Jupiter targets U.S. clinical and commercial channels, direct-to-consumer U.S. sales for nutritional products, and out-licensing and distribution partnerships in Southeast Asia and other international markets.

Summary from filing dated 2025-03-28

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Product Revenues, net	21,796	0	—
Cost of goods sold	4,231	—	—
Gross Profit	17,565	—	—
Research and development	2	492,660	954,793
General and administrative	7	3	3
Total operating expenses	9	3	4
Operating loss	−9	−3	−4
Interest income	—	5,557	482
Loss on change in fair value of derivative liability	—	−53,257	148,751
Gain on change in fair value of convertible notes	281,932	—	—
Interest expense	−66,020	−248,366	−218,705
Gain on extinguishment of debt	—	857,723	—
Other income	47,912	90,000	44,500
Total other expenses, net	263,824	651,657	−912,918
Net income (loss)	−9	−2	−5
Basic (per share)	−0.25	−0.08	−0.18
Diluted (per share)	−0.25	−0.08	−0.18
Basic (shares)	35	29	26
Diluted (shares)	35	29	26

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash	4	4	28,478	—
Account receivable	2,637	—	—	—
Prepaid contracts	766,667	766,667	—	—
Inventory, net	159,790	—	—	—
Other current assets	106,542	114,086	—	—
Total current assets	5	5	28,739	—
Operating lease right of use asset, net	23,214	69,642	116,070	—
Prepaid contracts, noncurrent	712,055	1	—	—
Other assets	3,783	3,783	3,783	—
Total assets	6	6	148,592	—
Accounts payable and accrued expenses	638,646	396,483	546,014	—
Accrued compensation	1	1	2	—
Accrued interest	39,829	1,064	88,000	—
Deferred revenue	735	—	—	—
Current portion of operating lease liability	21,247	50,082	48,213	—
Convertible notes payable, fair value	5	—	2	—
Other liability	—	—	—	—
Total current liabilities	7	2	6	—
Operating lease liability, net of current portion	—	21,247	71,329	—
Total liabilities	7	2	6	—
Commitments and Contingencies (Note 8)	—	—	—	—
Common stock, par value $0.0001; 500,000,000 and 125,000,000 shares authorized, respectively; 34,446,455 and 33,103,860 issued and outstanding, respectively	3,444	3,310	2,652	—
Additional paid in capital	33	30	18	—
Accumulated deficit	−35	−26	−24	—
Total stockholders deficit	−2	4	−6	−7
Total liabilities and stockholders deficit	6	6	148,592	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Amortization of debt discounts	—	43,288	16,712
Loss (Gain) on extinguishment of debt	—	−857,723	—
Gain on forgiveness of accrued compensation	—	−40,000	—
Amortization of prepaid contracts	766,666	54,612	—
Non-cash financing cost	200,000	—	—
Interest expense paid through sale of common stock	22,521	—	—
Stock-based compensation	2	2	1
Increase in accounts receivable	−2,637	—	—
Decrease (increase) in prepaid contracts	—	−2	—
Increase in prepaid and other current assets	—	−113,826	—
Increase in inventory	−159,790	—	—
Increase in other current assets	7,544	—	4,971
Decrease in operating lease right of use asset	−3,654	−1,785	25
Increase in deferred revenue	735	—	—
Increase in accounts payable and accrued expenses	242,163	−149,530	164,881
Decrease in accrued compensation	−17,736	−46,948	2
Increase in accrued interest	38,765	46,368	38,270
Net cash used in operating activities	−5	−4	−480,953
Proceeds from note payable, related parties	—	138,500	390,000
Payment on convertible note payable	—	−150,000	—
Proceeds from issuance convertible note payable, net	6	—	—
Proceeds from offering, net of offering costs	—	10	—
Proceeds from sale of common stock	—	150,000	55,000
Net cash provided by financing activities	5	8	445,000
Net Change in Cash	19,832	4	−35,953
Cash paid for interest	38,426	147,776	—
Restricted stock issued for forgiveness of salary	—	10,000	2
Stock options issued for forgiveness of salary	—	50,000	3
Notes payable, related party assign to Note payable	—	266,667	—
Stock issued in connection with convertible promissory notes	200,000	636,866	—
Stock issued in connection interest payment	22,521	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro